dc.contributor.author | Ibrahim, Mohamed | |
dc.contributor.author | Rabinowitz, Joshua | |
dc.contributor.author | Hilbert, Rebecca | |
dc.contributor.author | Ghose, Aruni | |
dc.contributor.author | Agarwal, Samita | |
dc.contributor.author | Swamy, Rajiv | |
dc.contributor.author | Bulut, Ismail | |
dc.contributor.author | Guttierrez, Mirian | |
dc.contributor.author | Buali, Ebtisam | |
dc.contributor.author | Nassar, Ekram | |
dc.contributor.author | Jhavar, Parag | |
dc.contributor.author | Al-Hashimi, Fatima | |
dc.contributor.author | Vasdev, Nikhil | |
dc.date.accessioned | 2024-03-25T13:30:23Z | |
dc.date.available | 2024-03-25T13:30:23Z | |
dc.date.issued | 2024-12 | |
dc.identifier.citation | Ibrahim , M , Rabinowitz , J , Hilbert , R , Ghose , A , Agarwal , S , Swamy , R , Bulut , I , Guttierrez , M , Buali , E , Nassar , E , Jhavar , P , Al-Hashimi , F & Vasdev , N 2024 , ' The role of URO17® in diagnosis and follow up of bladder cancer patients ' , BMC Urology , vol. 24 , no. 1 , 34 , pp. 1-7 . https://doi.org/10.1186/s12894-024-01426-7 | |
dc.identifier.issn | 1471-2490 | |
dc.identifier.uri | http://hdl.handle.net/2299/27516 | |
dc.description | ©2024 Crown. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY), https://creativecommons.org/licenses/by/4.0/ | |
dc.description.abstract | Objective: to evaluate the role of urinary URO17® biomarker in the detection of urothelial tumors in haematuria patients and the detection of recurrence in non-muscle invasive bladder urothelial tumors. Materials and methods: Our study was formed of two cohorts of patients, group I represents patients presenting with haematuria (n = 98), while group II represents patients with known non-muscle invasive bladder cancers on their scheduled follow up cystoscopic investigation (n = 51). For both groups, patients were asked to provide urine samples before cystoscopy, either primary as part of the haematuria investigation or as a scheduled follow-up. Urine samples were sent anonymously for standard urine cytology and URO17® biomarker immunostaining. Results were compared to cystoscopic findings using Chi-square analysis and Fisher’s exact test (P < 0.05). Results: Group I was formed of 98 patients, with an average age of 60 years. URO17® showed 100% sensitivity and 96.15% specificity with a negative predictive value (NPV) of 100 and a positive predictive value (PPV) of 95.83. The results showed statistical significance with P value < 0.001. Group II was formed of 51 patients, with an average age of 75 years. URO17® was shown to have a sensitivity of 85.71% and NPV of 95.45. Eleven patients of group II were on scheduled BacillusCalmette-Guerin (BCG) and another 5 received Mitomycin C (MMC). The overall results of both groups combined (n = 149) showed statistical significance between flexible cystoscopy results and the results of urinary URO17® and urine cytology. Conclusion: URO17® has a potential to be a reliable test for diagnosis and follow up of urothelial cancer patients and a screening tool adjunct to flexible cystoscopy. Trial Registration: Not applicable as the current study is not a clinical trial, as per according to the National Institutes of Health, “studies that involve a comparison of methods and that do not evaluate the effect of the interventions on the participant do not meet the NIH clinical trial definition.” | en |
dc.format.extent | 7 | |
dc.format.extent | 1176261 | |
dc.language.iso | eng | |
dc.relation.ispartof | BMC Urology | |
dc.subject | Bladder cancer | |
dc.subject | Non-muscle invasive tumor | |
dc.subject | URO17® | |
dc.subject | Urothelial cancer | |
dc.subject | cancer follow-up | |
dc.subject | Follow-Up Studies | |
dc.subject | Humans | |
dc.subject | Middle Aged | |
dc.subject | Cystoscopy | |
dc.subject | Urinary Bladder Neoplasms/pathology | |
dc.subject | Hematuria/diagnosis | |
dc.subject | Biomarkers | |
dc.subject | Urinary Bladder/pathology | |
dc.subject | Aged | |
dc.subject | Neoplasm Recurrence, Local/diagnosis | |
dc.subject | Urology | |
dc.subject | Reproductive Medicine | |
dc.title | The role of URO17® in diagnosis and follow up of bladder cancer patients | en |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Extracellular Vesicle Research Unit | |
dc.contributor.institution | Basic and Clinical Science Unit | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.description.status | Peer reviewed | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85184794825&partnerID=8YFLogxK | |
rioxxterms.versionofrecord | 10.1186/s12894-024-01426-7 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |